User login
Key clinical point: Ocrelizumab may be preferred over fingolimod as an exit strategy after natalizumab discontinuation in patients with relapsing-remitting multiple sclerosis (RRMS).
Major finding: At 1 year, fewer relapses were observed in patients receiving ocrelizumab vs fingolimod (0.12±0.39 vs 0.41±0.71; P = .035), realizing a 70.7% lower annualized relapse rate. The cumulative probability of relapse was significantly higher with fingolimod vs ocrelizumab (31.5% vs 10.4%; adjusted hazard ratio, 3.4; P = .04).
Study details: The data come from an observational, retrospective study involving 102 patients with RRMS who received either fingolimod (n=54) or ocrelizumab (n=48) after natalizumab cessation.
Disclosures: No source of funding was disclosed. Some of the authors including the lead author reported receiving consultancy fees and travel grants from various pharmaceutical companies.
Source: Bigaut K et al. J Neurol. 2022 Jan 4. doi: 10.1007/s00415-021-10950-7.
Key clinical point: Ocrelizumab may be preferred over fingolimod as an exit strategy after natalizumab discontinuation in patients with relapsing-remitting multiple sclerosis (RRMS).
Major finding: At 1 year, fewer relapses were observed in patients receiving ocrelizumab vs fingolimod (0.12±0.39 vs 0.41±0.71; P = .035), realizing a 70.7% lower annualized relapse rate. The cumulative probability of relapse was significantly higher with fingolimod vs ocrelizumab (31.5% vs 10.4%; adjusted hazard ratio, 3.4; P = .04).
Study details: The data come from an observational, retrospective study involving 102 patients with RRMS who received either fingolimod (n=54) or ocrelizumab (n=48) after natalizumab cessation.
Disclosures: No source of funding was disclosed. Some of the authors including the lead author reported receiving consultancy fees and travel grants from various pharmaceutical companies.
Source: Bigaut K et al. J Neurol. 2022 Jan 4. doi: 10.1007/s00415-021-10950-7.
Key clinical point: Ocrelizumab may be preferred over fingolimod as an exit strategy after natalizumab discontinuation in patients with relapsing-remitting multiple sclerosis (RRMS).
Major finding: At 1 year, fewer relapses were observed in patients receiving ocrelizumab vs fingolimod (0.12±0.39 vs 0.41±0.71; P = .035), realizing a 70.7% lower annualized relapse rate. The cumulative probability of relapse was significantly higher with fingolimod vs ocrelizumab (31.5% vs 10.4%; adjusted hazard ratio, 3.4; P = .04).
Study details: The data come from an observational, retrospective study involving 102 patients with RRMS who received either fingolimod (n=54) or ocrelizumab (n=48) after natalizumab cessation.
Disclosures: No source of funding was disclosed. Some of the authors including the lead author reported receiving consultancy fees and travel grants from various pharmaceutical companies.
Source: Bigaut K et al. J Neurol. 2022 Jan 4. doi: 10.1007/s00415-021-10950-7.